<VariationArchive VariationID="2130943" VariationName="NM_000384.3(APOB):c.6330del (p.Lys2110fs)" VariationType="Deletion" Accession="VCV002130943" Version="2" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-06" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2186238" VariationID="2130943">
      <GeneList>
        <Gene Symbol="APOB" FullName="apolipoprotein B" GeneID="338" HGNC_ID="HGNC:603" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p24.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791767.1" start="52097" stop="94741" display_start="52097" display_stop="94741" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="21001429" stop="21044073" display_start="21001429" display_stop="21044073" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="21224300" stop="21266944" display_start="21224300" display_stop="21266944" Strand="-" />
          </Location>
          <OMIM>107730</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000384.3(APOB):c.6330del (p.Lys2110fs)</Name>
      <CanonicalSPDI>NC_000002.12:21010537:TTTT:TTT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p24.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="21010538" stop="21010538" display_start="21010538" display_stop="21010538" variantLength="1" positionVCF="21010537" referenceAlleleVCF="AT" alternateAlleleVCF="A" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="21233410" stop="21233410" display_start="21233410" display_stop="21233410" variantLength="1" positionVCF="21233409" referenceAlleleVCF="AT" alternateAlleleVCF="A" />
      </Location>
      <ProteinChange>K2110fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.21233413del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.21233413del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.21010541del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.21010541del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011793.1" sequenceAccession="NG_011793" sequenceVersion="1" change="g.38536del">
            <Expression>NG_011793.1:g.38536del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011793.2" sequenceAccession="NG_011793" sequenceVersion="2" change="g.38535del">
            <Expression>NG_011793.2:g.38535del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000384.3" sequenceAccession="NM_000384" sequenceVersion="3" change="c.6330del" MANESelect="true">
            <Expression>NM_000384.3:c.6330del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000375.3" sequenceAccession="NP_000375" sequenceVersion="3" change="p.Lys2110fs">
            <Expression>NP_000375.3:p.Lys2110fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000384.3(APOB):c.6330del (p.Lys2110fs) AND multiple conditions" Accession="RCV003047950" Version="2">
        <ClassifiedConditionList TraitSetID="19838">
          <ClassifiedCondition DB="MedGen" ID="C4551990">Familial hypobetalipoproteinemia 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1704417">Hypercholesterolemia, autosomal dominant, type B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-08-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-08-27" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-02-08" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20032471</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="19838" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="18459" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, normotriglyceridemic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acanthocytosis with hypobetalipoproteinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial hypobetalipoproteinemia 1</ElementValue>
                <XRef ID="MONDO:0014252" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHBL1</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FHBL</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Individuals with biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction. Affected individuals typically have plasma total cholesterol, LDL cholesterol, and apo B levels below the fifth centile for age and sex. Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found. The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency. In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver. Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis. However, about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely.</Attribute>
                <XRef ID="NBK570370" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2876" />
                <XRef ID="2876" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">33983694</ID>
                <ID Source="BookShelf">NBK570370</ID>
              </Citation>
              <XRef ID="C4551990" DB="MedGen" />
              <XRef ID="MONDO:0014252" DB="MONDO" />
              <XRef Type="MIM" ID="615558" DB="OMIM" />
            </Trait>
            <Trait ID="1725" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Familial Hypercholesterolemia Type B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, autosomal dominant, type B</ElementValue>
                <XRef ID="MONDO:0007751" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APOLIPOPROTEIN B-100, FAMILIAL DEFECTIVE</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APOLIPOPROTEIN B-100, FAMILIAL LIGAND-DEFECTIVE</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LIGAND-DEFECTIVE APOLIPOPROTEIN B</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIb</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Familial hypercholesterolemia 2</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FHCL2</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">APOB-Related Familial Hypercholesterolemia, Autosomal Dominant</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8588" />
                <XRef ID="8588" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="C1704417" DB="MedGen" />
              <XRef ID="MONDO:0007751" DB="MONDO" />
              <XRef Type="MIM" ID="144010" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="6037560" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2023-02-07">
        <ClinVarSubmissionID localKey="16505908|MedGen:CN182502;C1704417" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV003352783" DateUpdated="2024-02-28" DateCreated="2023-02-07" Type="SCV" Version="2" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-08-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20032471</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Lys2110Asnfs*17) in the APOB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in APOB are known to be pathogenic (PMID: 20032471). This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with APOB-related conditions.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="APOB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.21233410del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN182502" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1704417" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="6037560" TraitType="Disease" MappingType="XRef" MappingValue="CN182502" MappingRef="MedGen">
        <MedGen CUI="C4551990" Name="Familial hypobetalipoproteinemia 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="6037560" TraitType="Disease" MappingType="XRef" MappingValue="C1704417" MappingRef="MedGen">
        <MedGen CUI="C1704417" Name="Hypercholesterolemia, autosomal dominant, type B" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

